These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17947686)

  • 1. Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
    Bos R; van Duikeren S; van Hall T; Lauwen MM; Parrington M; Berinstein NL; McNeil B; Melief CJ; Verbeek JS; van der Burg SH; Offringa R
    J Immunol; 2007 Nov; 179(9):6115-22. PubMed ID: 17947686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
    Hodge JW; McLaughlin JP; Kantor JA; Schlom J
    Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
    Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
    J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
    Ahn E; Kim H; Han KT; Sin JI
    Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
    Karanikas V; Lurquin C; Colau D; van Baren N; De Smet C; Lethé B; Connerotte T; Corbière V; Demoitié MA; Liénard D; Dréno B; Velu T; Boon T; Coulie PG
    J Immunol; 2003 Nov; 171(9):4898-904. PubMed ID: 14568971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
    Marshall JL; Hawkins MJ; Tsang KY; Richmond E; Pedicano JE; Zhu MZ; Schlom J
    J Clin Oncol; 1999 Jan; 17(1):332-7. PubMed ID: 10458251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine.
    Huang Y; Fayad R; Smock A; Ullrich AM; Qiao L
    Cancer Res; 2005 Aug; 65(15):6990-9. PubMed ID: 16061685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.
    Santra S; Schmitz JE; Kuroda MJ; Lifton MA; Nickerson CE; Lord CI; Pal R; Franchini G; Letvin NL
    J Immunol; 2002 Feb; 168(4):1847-53. PubMed ID: 11823518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines.
    Holst PJ; Sorensen MR; Mandrup Jensen CM; Orskov C; Thomsen AR; Christensen JP
    J Immunol; 2008 Mar; 180(5):3339-46. PubMed ID: 18292559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
    Liu J; Yu Q; Stone GW; Yue FY; Ngai N; Jones RB; Kornbluth RS; Ostrowski MA
    Vaccine; 2008 Jul; 26(32):4062-72. PubMed ID: 18562053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant cancer vaccines based on viral vectors.
    Moingeon P
    Dev Biol (Basel); 2004; 116():117-22; discussion 133-43. PubMed ID: 15603188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
    Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL
    Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.